ArticleCancer management and research2019
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier).
Erratum issuedAbstract read
In one paragraph
Article in Cancer management and research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Prognostic significance of systemic inflammatory indices in squamous cell carcinoma of the anal canal: A retrospective cohort study.Rare tumors · 2026Article
- Article
- Prognosis Prediction and Surgical Benefit Subgroup Analysis in Anal Squamous Cell Carcinoma Patients Undergoing Concurrent Chemoradiotherapy.Cancer medicine · 2025Article
- Emerging advances and future opportunities in the molecular and therapeutic landscape of anal cancer.Nature reviews. Clinical oncology · 2025Review
- Estimating Risk of Locoregional Failure and Overall Survival in Anal Cancer Following Chemoradiation: A Machine Learning Approach.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2023Article
- The Prognostic Role of Baseline Eosinophils in HPV-Related Cancers: a Multi-institutional Analysis of Anal SCC and OPC Patients Treated with Radical CT-RT.Journal of gastrointestinal cancer · 2023Article
- Influence of radiation treatment technique (IMRT vs. 3D-RT) on acute toxicity and prognostic factors for survival for anal cancer.Scientific reports · 2022Article
- Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index.Journal of gastrointestinal cancer · 2022Article
- Association of neutrophil-to-lymphocyte ratio, radiotherapy fractionation/technique, and risk of development of distant metastasis among patients with locally advanced rectal cancer.Radiation oncology (London, England) · 2022Article
- Do immune inflammatory markers correlate with anal dysplasia and anal cancer risk in patients living with HIV?International journal of colorectal disease · 2022Article
- A Machine-Learning-Based Bibliometric Analysis of the Scientific Literature on Anal Cancer.Cancers · 2022Article
- Prognostic impact of neutrophilia and lymphopenia on survival in anal cancer treated with definitive concurrent chemoradiotherapy: a retrospective multicenter study.International journal of clinical oncology · 2022Article
- Long term clinical outcomes and associated predictors of progression free survival in anal canal cancer.Journal of gastrointestinal oncology · 2022Article
- A predictive model of bowel resection for incarcerated inguinal hernia based on the systemic immune-inflammation index.Frontiers in surgery · 2022Article
- Construction and validation of a prognostic nomogram for anal squamous cell carcinoma.Cancer medicine · 2022Article
- Evolution of the Role of Radiotherapy for Anal Cancer.Cancers · 2021Review
- Article
- Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib.Medicine · 2020Observational
- Prognostic role of a new index (multi inflammatory index) in patients with metastatic colorectal cancer: results from the randomized ITACa trial.Therapeutic advances in medical oncology · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
25 authors.
Andrea Casadei-GardiniDepartment of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Francesco MontagnaniOncology Department, SOC Oncology, ASL (Health Local Authority), Biella, Italy.
Chiara CasadeiDepartment of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Francesca ArcadipaneDepartment of Oncology, Radiation Oncology, AOU Città della Salute e della Scienza, Turin, Italy.
Kalliopi AndrikouDepartment of Hematology and Oncology, University of Modena and Reggio Emilia, Modena, Italy.
Deborah AloiRadiation Oncology Department, Centre Hospitalier Régional Universitaire "Jean Minjoz", Besançon Cedex, France.
Alessandra Anna PreteUnit of Medical Oncology 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto, IRCCS, Padua, Italy.
Maria Giulia ZampinoDivision of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IRCCS, Milan, Italy.
Antonella ArgentieroMedical Oncology Unit, Cancer Institute Giovanni Paolo II, Bari, Italy.
Giuseppe PuglieseDepartment of Hematology and Oncology, University of Modena and Reggio Emilia, Modena, Italy.
Stefania MartiniDepartment of Oncology, Radiation Oncology, University of Turin, Turin, Italy.
Giuseppe Carlo IorioDepartment of Oncology, Radiation Oncology, University of Turin, Turin, Italy.
Mario ScartozziDepartment of Medical Oncology, University of Cagliari, Cagliari, Italy.
Massimiliano MistrangeloDepartment of Surgical Sciences, University of Turin, Turin, Italy.
Lorenzo FornaroUnit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana University, Pisa, Italy.
Paola CassoniDepartment of Medical Sciences, Pathology Unit, University of Turin, Turin, Italy.
Giorgia MarisiBiosciences Laboratory, Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.
Veronica Dell'AcquaDepartment of Radiotherapy, IRCCS, European Institute of Oncology, Milan, Italy.
Paola Simona RavendaDivision of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IRCCS, Milan, Italy.
Sara LonardiUnit of Medical Oncology 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto, IRCCS, Padua, Italy.
Nicola SilvestrisDepartment of Radiological, Oncological and Pathological Sciences, Policlinico Umberto I University Hospital, Rome, Italy.
Berardino De BariRadiation Oncology Department, Centre Hospitalier Régional Universitaire "Jean Minjoz", Besançon Cedex, France.
Umberto RicardiDepartment of Oncology, Radiation Oncology, AOU Città della Salute e della Scienza, Turin, Italy.
Stefano CascinuDepartment of Hematology and Oncology, University of Modena and Reggio Emilia, Modena, Italy.
Pierfrancesco FrancoMedical Oncology Unit, Cancer Institute Giovanni Paolo II, Bari, Italy.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
anal cancerNLRPLRprognostic factorsSII
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.